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ational Quality Improvement Initiative
ndra L. Blomkalns, MD,* Anita Y. Chen, MS,† Judith S. Hochman, MD,‡
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OBJECTIVES We hypothesized that significant disparities in gender exist in the management of patients
with non–ST-segment elevation (NSTE) acute coronary syndromes (ACS).
BACKGROUND Gender-related differences in the diagnosis and treatment of ACS have important healthcare
implications. No large-scale examination of these disparities has been completed since the
publication of the revised American College of Cardiology/American Heart Association
guidelines for management of patients with NSTE ACS.
METHODS Using data from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients
Suppress Adverse Outcomes with Early Implementation of the American College of
Cardiology/American Heart Association Guidelines) National Quality Improvement Initia-
tive, we examined differences of gender in treatment and outcomes among patients with
NSTE ACS.
RESULTS Women (41% of 35,875 patients) were older (median age 73 vs. 65 years) and more often had
diabetes and hypertension. Women were less likely to receive acute heparin, angiotensin-
converting enzyme inhibitors, and glycoprotein IIb/IIIa inhibitors and less commonly
received aspirin, angiotensin-converting enzyme inhibitors, and statins at discharge. The use
of cardiac catheterization and revascularization was higher in men, but among patients with
significant coronary disease, percutaneous revascularization was performed in a similar
proportion of women and men. Women were at higher risk for unadjusted in-hospital death
(5.6% vs. 4.3%), reinfarction (4.0% vs. 3.5%), heart failure (12.1% vs. 8.8%), stroke (1.1% vs.
0.8%), and red blood cell transfusion (17.2% vs. 13.2%), but after adjustment, only transfusion
was higher in women.
CONCLUSIONS Despite presenting with higher risk characteristics and having higher in-hospital risk, women
with NSTE ACS are treated less aggressively than men. (J Am Coll Cardiol 2005;45:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.11.055832–7) © 2005 by the American College of Cardiology Foundation
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Pardiovascular disease, primarily coronary heart disease, is
he leading cause of death for women. In 2001, women
omprised 53.6% (n  498,863) of all deaths from cardio-
ascular disease (1). Although advances in the diagnosis and
reatment of acute coronary syndromes (ACS) have resulted
n a decrease in coronary heart disease mortality during the
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ridge, Massachusetts) and Schering Corp. (Kenilworth, New Jersey). Bristol-Myers 2ourse of the last decade among men, the death rate among
omen continues to increase, and more women than men
ave died of cardiovascular disease in every year since 1984
1). Furthermore, women have higher rates of recurrent
yocardial infarction (MI) and age-adjusted mortality after
heir first MI (2). Thirty-eight percent of women who have
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March 15, 2005:832–7 Gender Disparities in Non–ST-Segment Elevation ACSn MI die within one year compared with 25% of men.
ithin six years of an MI, 35% of women will have another
I, sudden cardiac death will claim the lives of 6%, and
6% will be disabled with heart failure (1).
Most of the literature regarding the diagnosis and man-
gement of coronary heart disease and ACS is supported by
tudies performed in predominantly male populations. Al-
hough several recent studies raised concerns about differing
esponses to some therapies among male and female sub-
roups (3–5), other studies have challenged these findings
6–8), and for most therapies, the weight of evidence
upports use in both women and men (9).
The American College of Cardiology (ACC) and the
merican Heart Association (AHA) recently published
pdated guidelines for the management of patients with
nstable angina and non–ST-segment elevation (NSTE)
I, the two conditions that collectively make up NSTE
CS (9). The recommendations contained in the guidelines
re “gender-neutral,” but no large-scale assessment of gen-
er disparity has been undertaken since their release. We
ypothesized that, despite widely disseminated guidelines
or the treatment of these patients, gender differences would
till exist.
The CRUSADE (Can Rapid Risk Stratification of Un-
table Angina Patients Suppress Adverse Outcomes with
arly Implementation of the ACC/AHA Guidelines) Na-
ional Quality Improvement Initiative is designed to track
dherence to guidelines, provide feedback about perfor-
ance, and develop quality-improvement tools to improve
dherence to guidelines recommendations. In this analysis,
e used the CRUSADE data to perform the first large-
cale, practice-based examination of gender disparities in
he diagnosis and treatment of patients with NSTE ACS.
ata from the CRUSADE initiative revealed that women
re treated very differently than men, and we suggest reasons
nd potential solutions for these differences.
ETHODS
atient population. Data from 40,912 patients presenting
ith NSTE ACS at 391 U.S. hospitals participating in the
RUSADE initiative between March 31, 2000, and
ecember 31, 2002, were available at the time of this
Abbreviations and Acronyms
ACC  American College of Cardiology
ACS  acute coronary syndromes
AHA  American Heart Association
CRUSADE  Can Rapid Risk Stratification of Unstable
Angina Patients Suppress Adverse
Outcomes with Early Implementation of
the ACC/AHA Guidelines
GP  glycoprotein
MI  myocardial infarction
NSTE  non–ST-segment elevationnalysis. Specifics of the CRUSADE initiative’s educational ifforts and quality-improvement goals have been described
lsewhere (10). Briefly, the CRUSADE initiative collects
emographic, diagnostic, treatment, and in-hospital out-
ome data on patients who meet the diagnostic criteria of
igh-risk NSTE ACS (ischemic symptoms at rest lasting
or at least 10 min within 24 h before presentation and
igh-risk features, including ST-segment depression 0.5
m, transient ST-segment elevation 0.5 to 1.0 mm [lasting
or 10 min], and/or positive cardiac markers [elevated
roponin I or T and/or creatine kinase-myocardial band 
pper limit of normal for the local laboratory assay]).
reatment patterns and compliance with the ACC/AHA
uidelines are collected by each site and aggregated in a
entral database. Individual site performance on selected
uality indicators in NSTE ACS care, national norms, and
he 10th and 90th percentiles are provided rapidly to
ndividual sites to quantify their performance and to facili-
ate their quality-improvement efforts.
tatistical methods. The goal of our analysis was to
xplore the relations of gender, the use of guideline-
ecommended in-hospital care, and in-hospital clinical out-
omes. Patients excluded from this analysis included those
ho were transferred to another hospital, which resulted in
ncomplete information on baseline and discharge therapy
se and in-hospital outcomes (3,210 men and 1,827
omen), and patients with missing gender status (n  66).
n determining the frequency of use of each guidelines-
ecommended medication, only patients without docu-
ented contraindications to a given medication were con-
idered eligible to receive that medication and were included
n the denominator (10). Our final analysis population
ncluded 35,875 individuals.
Patient characteristics, care patterns, and outcomes were
ompared between men and women. We reported medians
25th, 75th percentiles) for continuous variables and fre-
uencies for categorical variables. Wilcoxon rank-sum and
hi-square tests were used to evaluate gender differences in
ontinuous and categorical variables, respectively.
In examining the relationships between a patient’s gender
nd care patterns and outcomes, we adjusted for variables
ollected in the CRUSADE registry as described previously
11). These variables included baseline patient clinical risk
actors, including age, body mass index, race, family history
f coronary artery disease, hypertension, diabetes, smoking
tatus, hypercholesterolemia, previous MI, previous percu-
aneous coronary intervention, previous coronary artery
ypass grafting, previous congestive heart failure, previous
troke, renal insufficiency, ST-segment depression, transient
T-segment elevation, positive cardiac markers, signs of
ongestive heart failure, heart rate, systolic blood pressure,
nd insurance status, as well as for provider and hospital
haracteristics (physician specialty; total number of hospital
eds; region of the country; presence of cardiac catheteriza-
ion, coronary intervention, and bypass surgery facilities;
nd type of hospital—academic or nonacademic). General-
zed estimating equation models were used to adjust for
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Gender Disparities in Non–ST-Segment Elevation ACS March 15, 2005:832–7orrelations among clustered responses (e.g., within-
ospital correlations because patients within a single hospi-
al are more likely to be similar) (12). For all tests,
ifferences were considered significant at p  0.05. All
nalyses were performed using SAS software (version 8.2,
AS Institute, Cary, North Carolina).
ESULTS
atient characteristics. Among the 35,875 patients in-
luded in our analysis, 14,552 (41%) were women. Women
ere significantly older than men and smoked less often,
ad hyperlipidemia, or had a family history of coronary
rtery disease but more often had diabetes and hypertension
Table 1). Fewer women had a history of MI, percutaneous
oronary intervention, or coronary artery bypass grafting.
ore women presented with a history of congestive heart
ailure and with active signs of congestive heart failure on
resentation. Women were less likely to be cardiac marker-
ositive or to have transient ST-segment elevation but more
ften had ST-segment depression at presentation, although
hese differences were small.
reatment patterns. Women were less likely to have an
lectrocardiogram (ECG) performed within 10 min of
ospitalization presentation (25.2% vs. 29.3% for men) and
ere less commonly cared for by a cardiologist during the
npatient hospitalization (53.4% vs. 63.4% for men).
Treatment disparities were present for women with both
cute (within 24 h) and discharge medications (Table 2).
fter adjustment, women were less likely to receive acute
eparin and acute angiotensin-converting enzyme inhibi-
ors. In addition, regardless of troponin results, women were
ess often treated acutely with glycoprotein (GP) IIb/IIIa
Table 1. Baseline Clinical Characteristics
Variable
Age (yrs)
Body mass index (kg/m2)
Family history of coronary artery disease (%)
History of hypertension (%)
Diabetes (%)
Insulin-dependent diabetes mellitus (%)
Non–insulin-dependent diabetes mellitus (%)
Current/recent smoker (%)
Hypercholesterolemia (%)
Previous myocardial infarction (%)
Previous percutaneous coronary intervention (%)
Previous coronary artery bypass grafting (%)
Previous congestive heart failure (%)
Previous stroke (%)
Renal insufficiency (%)
Presenting characteristics
ST-segment depression (%)
Transient ST-segment elevation (%)
Positive cardiac marker (%)
Signs of congestive heart failure (%)
Age and body mass index are presented as median (25th, 75nhibitors. Similar treatment patterns existed for discharge tedication use, as women were significantly less likely to
eceive aspirin, angiotensin-converting enzyme inhibitors,
nd statins compared with men (Table 2).
Table 3 shows differences in the use of procedures. Men
ore frequently underwent diagnostic catheterization,
hereas women were more likely to undergo stress testing.
evascularization procedures were performed less frequently
n women. However, the likelihood of percutaneous coro-
ary intervention was similar among men and women who
nderwent diagnostic catheterization (adjusted odds ratio
.97; 95% confidence interval 0.91 to 1.03) and among
hose who were found to have significant coronary disease
70% obstruction in one, two, or three major epicardial
oronary vessels) during catheterization (adjusted odds ratio
.04; 95% confidence interval 0.98 to 1.12).
linical outcomes. The frequencies of unadjusted adverse
utcomes were higher in women compared with men (Table
). However, after adjustment, only the risk of red blood cell
ransfusion was higher in women.
ISCUSSION
sing the CRUSADE data, we are able to provide the first
arge-scale, contemporary examination of the diagnosis and
reatment of patients with NSTE ACS across the U.S. since
he revision of the ACC/AHA guidelines for the manage-
ent of patients with NSTE ACS. Despite the widespread,
ultidisciplinary dissemination of this evidence-based con-
ensus document, most accepted treatments remain under-
sed in this high-risk patient population. In our study, we
ound that although women with NSTE ACS are at higher
isk for unadjusted adverse clinical outcomes during hospi-
alization, they less often received guidelines-recommended
verall
35,875)
Male
(n  21,323)
Female
(n  14,552)
56.0, 78.0) 65.0 (54.0, 76.0) 73.0 (61.0, 82.0)
24.3, 31.7) 27.8 (24.8, 31.5) 27.3 (23.4, 32.1)
37.0 38.4 34.9
69.7 66.2 74.8
32.6 30.6 35.6
12.1 10.3 14.7
21.7 21.3 22.2
27.9 32.0 21.8
47.1 48.8 44.5
32.0 34.0 29.2
22.4 24.5 19.3
21.0 24.7 15.6
19.0 16.2 23.2
11.0 10.0 12.6
13.9 13.8 14.0
41.4 40.4 42.9
10.5 11.1 9.5
86.6 87.7 84.8
22.7 19.8 26.9
centile).O
(N 
68.0 (
27.6 (herapy than men. Several differences were noted in both
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March 15, 2005:832–7 Gender Disparities in Non–ST-Segment Elevation ACSiagnostic and treatment measures. Time to ECG was
onger for women than for men, women were less likely to
e cared for by a cardiologist, and invasive diagnostic
easures and treatments were less frequently used in
omen. Moreover, even when invasive diagnostic and
herapeutic interventions were used, women waited longer
o receive them. Both acute and discharge guidelines-
ecommended medical therapies were consistently applied
ess often to female patients. These patterns of relative
nderuse in women were similar whether considering older,
ore established therapies, such as aspirin and heparin, or
ewer, perhaps more controversial ones, such as clopidogrel.
n addition, GP IIb/IIIa inhibitors were used less often in
he acute setting, even when only troponin-positive women
nd men were considered.
Treatment disparities demonstrated in this analysis are
imilar to those in previous studies that found women to be less
ggressively diagnosed and treated than men (13–15). In one of
he largest studies to date, the National Registry of Myocardial
nfarction-1 investigators found that similar patterns existed
mong ST-segment elevation patients with MI (2). Using a
atabase of 354,435 patients at 1,234 U.S. hospitals, important
able 2. Use of Medical Treatment by Gender With Odds Ratio
Variable
Male
(n  21,323)
reatment within 24 h
Aspirin 91.6%
Heparin, any 84.0%
Unfractionated heparin 54.8%
Low molecular weight heparin 35.9%
Glycoprotein IIb/IIIa inhibitor, any 38.6%
Troponin-positive 39.9%
Troponin-negative 29.0%
Beta-blocker 77.7%
Angiotensin-converting enzyme inhibitor 42.2%
Clopidogrel 41.0%
ischarge medications
Aspirin 90.4%
Beta-blocker 82.7%
Angiotensin-converting enzyme inhibitor 55.5%
Statin 63.4%
Clopidogrel 53.2%
Reference is male; variables in model listed in methods.
CI  confidence interval; OR  odds ratio.
able 3. Use of In-Hospital Procedures by Gender With Odds R
Variable
Male
(n  21,323)
oninvasive stress testing 11.7%
iagnostic catheterization 71.1%
atheterization 24 h of arrival 48.7%
Arrival to catheterization (h)† 22.6 (7.2, 45.9)
ercutaneous coronary intervention (PCI) 40.4%
PCI 24 h of arrival 51.9%
Arrival to PCI, (h)† 21.0 (4.7, 44.2)
oronary artery bypass grafting 14.0%
Variables in the model are same as in Table 2. Data are presented as percentages ex
25th, 75th percentile). †For continuous variables, data presented are unadjusted or adjuste
Abbreviations as in Table 2.ender-related differences in treatment were observed. Ac-
epted pharmacologic interventions, such as aspirin, beta-
lockers, and heparin, were used less frequently in women, and
hrombolytic therapy was administered, on average, 14 min
ater in women than men. Women also were less likely to
eceive invasive procedures, such as cardiac catheterization,
ercutaneous coronary intervention, and coronary artery bypass
rafting, and insignificant disease on catheterization more
ften was noted in women compared with men (11.5% vs.
.0%, p  0.0001). Our analyses, which reveal similar rates of
ercutaneous coronary intervention use among women and
en after accounting for use of diagnostic angiography and
xtent of coronary disease, suggest that observed gender-
elated differences in the use of revascularization procedures
tem primarily from disparities in the use of angiography
nd/or the extent of disease rather than in the use of revascu-
arization itself. Thus, the literature has clearly documented
ender disparities in the management of ACS, and our
ndings of a continued trend for women to less often receive
uidelines-recommended treatment, despite the clear gender-
eutrality of the ACC/AHA guidelines, are concerning, par-
icularly given women’s higher overall risk.
Use in Women Relative to Men
Female
(n  14,552)
Unadjusted
OR
Adjusted* OR
(95% CI)
89.6% 0.83 0.93 (0.86–1.01)
80.0% 0.80 0.91 (0.86–0.97)
48.5% 0.81 0.91 (0.87–0.95)
37.7% 1.07 1.03 (0.98–1.08)
28.7% 0.68 0.86 (0.81–0.92)
30.5% 0.69 0.87 (0.81–0.92)
19.4% 0.68 0.81 (0.71–0.93)
75.8% 0.94 1.01 (0.95–1.06)
42.4% 1.03 0.95 (0.90–0.99)
35.6% 0.82 0.97 (0.92–1.01)
87.5% 0.79 0.91 (0.85–0.98)
80.5% 0.89 0.94 (0.88–1.00)
55.3% 1.01 0.93 (0.88–0.98)
55.9% 0.77 0.92 (0.88–0.98)
48.0% 0.84 1.01 (0.96–1.06)
for Use in Women Relative to Men
Female
(n  14,552)
Unadjusted
OR
Adjusted* OR
(95% CI)
13.2% 1.10 1.07 (1.00–1.14)
60.1% 0.70 0.86 (0.82–0.91)
42.1% 0.69 0.87 (0.82–0.92)
6.5 (12.4, 53.9) 1.16 1.08 (1.02–1.14)
31.4% 0.73 0.91 (0.86–0.96)
44.3% 0.64 0.85 (0.79–0.91)
5.2 (9.0, 52.8) 1.17 1.06 (0.99–1.19)
9.0% 0.62 0.59 (0.54–0.64)
rrival to catheterization and arrival to percutaneous coronary intervention  medians foratios
2
2
cept a
d estimate and 95% CI for adjusted estimate.
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Gender Disparities in Non–ST-Segment Elevation ACS March 15, 2005:832–7The undertreatment of female patients with NSTE ACS
s likely multifactorial. One possible explanation might be
iagnostic uncertainty when physicians are presented with
emale patients. The uncertainties caused by a lower age-
djusted frequency of coronary artery disease among women
resenting with symptoms of possible ACS and delays in
ymptom recognition in women might translate to delays in
CG acquisition and undertreatment. However, these fac-
ors cannot explain the management deficits we observed,
ecause to be included in the CRUSADE initiative, patients
ad to have been diagnosed with high-risk NSTE ACS and
herefore should have received similar consideration.
In our study, women with NSTE ACS more often were
dmitted to the care of a noncardiologist. This might
xplain the lower use of newer, perhaps more aggressive
ardiologist-specific therapies, such as clopidogrel and GP
Ib/IIIa inhibitors in women, as well as the lower use of
nvasive therapies. However, it does not adequately explain
he less frequent use of older, more established therapies
uch as aspirin and heparin. Women in the CRUSADE
nitiative also were less likely to present with positive
roponin levels and were more likely to present with
T-segment depression. Although these differences in pre-
entation may affect choice of therapy or intervention, our
nalyses suggest that it is unlikely that these differences
lone drove the observed disparities.
As would be expected, women were older, and many had
igh-risk baseline features. Although such features contrib-
te to increased risk and thus portend greater absolute
reatment benefits, these characteristics often are associated
ith undertreatment, in part because of the lack of clinical
rials evidence in these groups and in part because of fear of
omplications. The “do-no-harm” adage may actually pre-
lude clinicians from actively treating these patients without
he understanding that such undertreatment might be the
ore harmful choice. One perceived obstacle in treating
lder women might be related to an increased incidence of
leeding, which was reflected by an increased rate of red
lood cell transfusion in our study.
Despite the clear underuse of recommended therapies in
omen, adjusted in-hospital outcomes were not different
etween men and women. Gan et al. (16) noted a similar
attern of less aggressive treatment without a concomitant
able 4. In-Hospital Clinical Outcomes by Gender With Odds R
Outcome
Male
(n  21,323)
eath 4.3%
eath or myocardial infarction 7.1%
ostadmission myocardial infarction 3.5%
ardiogenic shock 2.7%
ongestive heart failure 8.8%
troke 0.8%
ed blood cell transfusion 13.2%
Variables in the model same as Tables 2 and 3.
Abbreviations as in Table 2ffect on early mortality in patients with acute MI. This pattern Aikely reflects both the influence of a greater prevalence of
igh-risk comorbidities in women than in men and the
nfluence of unmeasured selection biases in the use of therapies
hat make comparisons of the effect of therapies in observa-
ional datasets challenging. Only when all patients receive
ppropriate, similar treatment strategies will we be able to
onfidently answer the question of their effect on outcome.
tudy limitations. The results from the CRUSADE ini-
iative represent the largest examination of gender differ-
nces in NSTE ACS treatment to date. Given the large
umber of patients in the CRUSADE database, many of
he differences noted in this study are relatively small but
tatistically significant. The clinical significance of these
ifferences should be considered when interpreting our
esults. Additionally, patients transferred to other care
acilities were excluded from our analysis because current
rivacy regulations, which prohibit the collection of anon-
mous data after interhospital transfer. Although this situ-
tion represents a significant number of patients (3,210 men
13%] and 1,827 women [11%]), the proportion of men and
omen in these groups is similar and therefore cannot
ccount for differences in treatment, and differences in
ardiac catheterization rates in particular.
onclusions. Women make up more than 40% of patients
resenting with high-risk NSTE ACS in the CRUSADE
nitiative. The risk for in-hospital complications, including
eath, is 15% to 20% higher for women compared with men,
n part because of greater comorbidities. Despite women being
t greater risk, we found that guidelines-recommended medical
nd interventional strategies are used significantly less fre-
uently in women than in men. These pervasive and continu-
ng gender disparities represent a significant opportunity for
uality improvement in the care of patients with NSTE ACS.
arriers that contribute to treatment disparities in women and
he influence of other clinical characteristics on differences in
reatment patterns and outcomes among women and men
equire further investigation.
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ocation 0769, University of Cincinnati College of Medicine, 231
lbert Sabin Way, Cincinnati, Ohio 45267-0769. E-mail:
s for Clinical Outcomes in Women Relative to Men
emale
14,552)
Unadjusted
OR
Adjusted* OR
(95% CI)
5.6% 1.27 1.01 (0.90–1.13)
8.6% 1.17 1.02 (0.93–1.11)
4.0% 1.12 1.08 (0.97–1.20)
3.1% 1.10 1.01 (0.87–1.18)
12.1% 1.35 1.07 (0.99–1.17)
1.1% 1.37 1.13 (0.88–1.44)
17.2% 1.37 1.17 (1.09–1.25)atio
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